Oncology News | pharmaphorum

News

NICE says no to Merck Serono's Bavencio in bladder cancer

Merck Serono's Bavencio is the only checkpoint inhibitor to be approved for first-line maintenance treatment of bladder cancer in Europe, but UK cost-effectiveness agency NICE says it is to

News

AstraZeneca's (AZ) Tagrisso (osimertinib)

Patients in England get fast access to AZ's Tagrisso in earl...

The UK’s drugs regulator has swiftly granted a licence extension for AstraZeneca’s Tagrisso in certain patients with early stage lung cancer, with NICE allowing fast access to patients on E

News

Roche's Tecentriq gets fourth European NSCLC indication

Roche’s cancer immunotherapy Tecentriq has been granted a new use by European regulators, for the first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC)

News

Janssen J&J Johnson and Johnson pharmaceutical companies

Janssen files its first CAR-T therapy cilta-cel in Europe

Johnson & Johnson’s Janssen unit has filed for approval of its multiple myeloma CAR-T ciltacabtagene autoleucel in Europe, chasing after a rival therapy from Bristol-Myers Squibb.

News

Keytruda should lose stomach cancer indication, says ODAC

The FDA's Oncologic Drugs Advisory Committee (ODAC) has voted to strip Merck & Co's Keytruda of its accelerated approval in gastric and gastroesophageal junction (GEJ) cancer, despite a

News

Tecentriq can stay as therapy for triple-negative breast can...

Roche’s Tecentriq can stay on the US market as a therapy for triple negative breast cancer, advisers to the FDA have said as part of a review of several quickly-approved cancer drugs.

NICE says no to Merck Serono's Bavencio in bladder cancer

Patients in England get fast access to AZ's Tagrisso in earl...

Roche's Tecentriq gets fourth European NSCLC indication

Janssen files its first CAR-T therapy cilta-cel in Europe

Keytruda should lose stomach cancer indication, says ODAC

Tecentriq can stay as therapy for triple-negative breast can...

GSK to quit Stevenage for new R&D site in Cambridge

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks